Real-World Study of Camrelizumab-based Regimen for Locally Advanced and Metastatic Esophageal Cancer
Background Camrelizumab is a PD-1 inhibitor independently developed in China, which has been approved for use in the treatment of esophageal cancer. However, its efficacy and safety data in clinical practice are still lacking. Objective This study is aimed at assessing the Camrelizumab-based regimen...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Chinês |
| منشور في: |
Chinese General Practice Publishing House Co., Ltd
2025-03-01
|
| سلاسل: | Zhongguo quanke yixue |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.chinagp.net/fileup/1007-9572/PDF/20230448.pdf |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|